Siyuan Zhang

Siyuan Zhang

Auto-generated profile, based on publicly available information

Siyuan Zhang

Department of Pathology, UT Southwestern Medical Center, Dallas, TX, 75390, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2015 in Nature
Verified
Journal Article
Closed access
PDF file
LZLin Zhang
Lin Zhang
SZSiyuan Zhang
Siyuan Zhang
JYJun Yao
Jun Yao
FLFrank J. Lowery
Frank J. Lowery
QZQingling Zhang
Qingling Zhang
DYDihua Yu
Dihua Yu

13 March 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SZSiyuan Zhang
Siyuan Zhang
WHWen-Chien Huang
Wen-Chien Huang
PLPing Li
Ping Li
HGHua Guo
Hua Guo
SPSay-Bee Poh
Say-Bee Poh
DYDihua Yu
Dihua Yu


15 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
DEDeanna N. Edwards
Deanna N. Edwards
VNVerra M. Ngwa
Verra M. Ngwa
ARAriel L. Raybuck
Ariel L. Raybuck
SWShan Wang
Shan Wang
YHYoonha Hwang
Yoonha Hwang
JCJin Chen
Jin Chen
Rapidly proliferating tumor and immune cells need metabolic programs that support energy and biomass production. The amino acid glutamine is consumed by effector T cells and glutamine-addicted triple-negative breast cancer (TNBC) cells, suggesting that a metabolic competition for glutamine may exist within the tumor microenvironment, potentially serving as a therapeutic intervention strategy. Here, we report that there is an inverse correlation between glutamine metabolic genes and markers of T cell–mediated cytotoxicity in human basal-like breast cancer (BLBC) patient data sets, with increased glutamine metabolism and decreased T cell cytotoxicity associated with poor survival. We found that tumor cell–specific loss of glutaminase (GLS), a key enzyme for glutamine metabolism, improved antitumor T cell activation in both a spontaneous mouse TNBC model and orthotopic grafts. The glutamine transporter inhibitor V-9302 selectively blocked glutamine uptake by TNBC cells but not CD8+ T cells, driving synthesis of glutathione, a major cellular antioxidant, to improve CD8+ T cell effector function. We propose a “glutamine steal” scenario, in which cancer cells deprive tumor-infiltrating lymphocytes of needed glutamine, thus impairing antitumor immune responses. Therefore, tumor-selective targeting of glutamine metabolism may be a promising therapeutic strategy in TNBC.

1 March 2012 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
SZSiyuan Zhang
Siyuan Zhang
DYDihua Yu
Dihua Yu

1 May 2005 in Current Medicinal Chemistry - Anti-Cancer Agents
Verified
Journal Article
Closed access
PDF file
SZSiyuan Zhang
Siyuan Zhang
YWYen-Kim Won
Yen-Kim Won
COChoon Nam Ong
Choon Nam Ong
HSHan-Ming Shen
Han-Ming Shen
Sesquiterpene lactones (SLs) are the active constituents of a variety of medicinal plants used in traditional medicine for the treatment of inflammatory diseases. In recent years, the anti-cancer property of various SLs has attracted a great deal of interest and extensive research work has been carried out to characterize the anti-cancer activity, the molecular mechanisms, and the potential chemopreventive and chemotherapeutic application of SLs. In this review, we attempt to summarize the current knowledge of the anti-cancer properties of SLs by focusing on the following important issues. First, we discuss the structure-activity relationship of SLs. All SLs contain a common functional structure, an α- methylene-γ-lactone group, and this important chemical characteristic means that the thiol-reactivity of SLs is an underlying mechanism responsible for their bioactivities. Second, we assess the experimental evidence for the anti-cancer function of SLs obtained from both in vitro cell culture and in vivo animal models. Various SLs have been demonstrated to execute their anti-cancer capability via inhibition of inflammatory responses, prevention of metastasis and induction of apoptosis. Thirdly, we outline the molecular mechanisms involved in the anti-cancer activity of SLs, in particular, the SLthiols reaction, the effect of SLs on cell signaling pathways such as nuclear transcription factor-kappaB (NF-κB) and mitogen-activated protein kinases (MAPK). Finally, we recapitulate some important SLs with regards to their anti-cancer activities and their potential in anti-cancer drug development. Taken together, many SLs are emerging as promising anticancer agents with potential applications in both cancer chemotherapy and chemoprevention.